Efficacy of Enzalutamide Plus Androgen Deprivation Therapy In Metastatic Hormone-Sensitive Prostate Cancer By Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

Andrew J. Armstrong, Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, and Arnulf Stenzl

Click here to read the article.

Comparison of Germline Mutations In African American And Caucasian Men With Metastatic Prostate Cancer

Elisa M. Ledet PhD, Earle F. Burgess MD, Alexandra O. Sokolova MD, Ellen B. Jaeger BS, Whitley Hatton MS, Marcus Moses MS, Patrick Miller MPH, Patrick Cotogno MS, Jodi Layton MD, Pedro Barata MD, Brian E. Lewis MD, Mari Nakazawa MD, Jason Zhu MD, Beth Dellinger MS, Sara Elrefai MD, Nellie N. Nafissi MD, Jan B. Egan PhD, Neal Shore MD, Rana R. McKay MD, Alan H. Bryce MD, Heather H. Cheng MD, PhD, Emmanuel S. Antonarakis MD, Oliver Sartor MD

Click here to register for free to gain access to the article.

Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)

Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean-Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N. V. S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh & Arash Rezazadeh Kalebasty

Click here to read the article.

Treatment of Nonmetastatic Castration- Resistant Prostate Cancer: Focus On Second-Generation Androgen Receptor Inhibitors

Fred Saad, Martin Bögemann, Kazuhiro Suzuki & Neal Shore

Click here to read more.

Treating The Patient And Not Just The Cancer: Therapeutic Burden In Prostate Cancer

Daniel E. Spratt, Neal Shore, Oliver Sartor, Dana Rathkopf & Kara Olivier

Click here to read more.

Dr. Shore Discusses Hormonal Therapy In Prostate Cancer For Learning Clinicians

Dr. Shore, an expert in urologic oncology, discusses hormonal therapy in prostate cancer. He leads an educational discussion and course on prostate cancer for learning clinicians. The activity has been designed to meet the educational needs of oncologists, urologists, advanced practice clinicians, and other professionals involved in the management of patients with prostate cancer. 

For clinicians to access the course use the link below to access the course and begin the pre-test. In order to receive CME credit, participants must view the activity and complete the post-test and evaluation form. 

Click here to take the course and watch the discussion




Dr. Shore & Colleagues Host A 4-Part Interactive Webinar Series For Learning Clinicians

Key Issues For The Advanced Bladder Cancer Clinic: Incorporating Immunotherapy Into Your Community-Based Urology Practice

Join Dr. Neal Shore and his esteemed colleagues for this four-part webinar series focused on the implementation of IO, as well as other recently approved advanced bladder cancer therapies. This series was designed for all clinicians interested in bladder cancer treatment, but especially for those dedicated community urology practices desiring to establish an advanced bladder cancer clinic of excellence. 
Earn 1.0 Credit hours (ACCME/ACPE/ANCC) for each webinar.

For clinicians, to view the interactive webinars, click the link below and choose which webinar you would like to begin. Then log in or register to gain access and begin the course.

Click here to access the interactive webinars

Dr. Shore’s article chosen as a NEJM “Most Notable Articles of 2020”

Neal Shore, MD, Article Featured in Notable Articles of 2020 by The New England Journal of Medicine.

The New England Journal of Medicine editors have selected Dr. Shore’s article Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer to be featured in Notable Articles of 2020. This is a selection of articles that have been the most meaningful in changing medical practice and improving patient care in 2020.


To access this article please click the link below for The New England Journal of Medicine’s website and create a free log-in. Once logged into your account, the collection will be accessible under the “Special Offers” tab.

Click here for the New England Journal of Medicine’s website.

Neal Shore, MD, FACS: Relugolix Approval for Advanced Prostate Cancer

Interview with Neal Shore, MD, FACS, about the approval of Relugolix for advanced prostate cancer and the significance of the treatment.

Click here to read more.